Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism

TY - JOUR

T1 - Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism

AU - Vestergaard, H

AU - Lund, S

AU - Pedersen, O

AU - Vestergaard, Henrik

PY - 2001/11

Y1 - 2001/11

N2 - Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.

AB - Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.

KW - Adolescent

KW - Adult

KW - Apolipoproteins B

KW - Body Mass Index

KW - Diabetes Complications

KW - Diabetes Mellitus

KW - Fatty Acids, Nonesterified

KW - Humans

KW - Hyperglycemia

KW - Hypoglycemic Agents

KW - Insulin

KW - Insulin Resistance

KW - Male

KW - Mutation

KW - Plasminogen Activator Inhibitor 1

KW - Receptor, Insulin

KW - Thiazoles

KW - Thiazolidinediones

KW - Triglycerides

M3 - Journal article

C2 - 11887975

SN - 0955-7873

VL - 250

SP - 406

EP - 414

JO - Acta Medica Scandinavica

JF - Acta Medica Scandinavica

IS - 5

ER -